Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The pathological anatomy laboratory, which is managed by the IPG, would involve monitoring patients being treated for cancer and receiving care at the GHDC in order to take blood samples from those in whom the presence of plasma ctDNA carrying a mutation in a specific gene is suspected - a mutation detectable by the TST79 test.
Epistemonikos ID: b5c5b60916b0649ed2e963c3f9208a64546aa6f7
First added on: Oct 10, 2026